Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports
Introduction In late 2019, a new coronavirus—severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)—was discovered in Wuhan, China, and the World Health Organization later declared coronavirus disease 2019 (COVID-19) a pandemic. Numerous drugs have been repurposed and investigated for therapeutic effectiveness in the disease, including those from “Solidarity,” an international clinical trial (azithromycin, chloroquine, hydroxychloroquine, the fixed combination lopinavir/ritonavir, and remdesivir). Objective Our objective was to evaluate adverse drug reaction (ADR) reporting for drugs when used in the treatment of COVID-19 compared with use for other indications, specifically focussing on sex differences. Method We extracted reports on COVID-19-specific treatments from the global ADR database, VigiBase, using an algorithm developed to identify reports that listed COVID-19 as the indication. The Solidarity trial drugs were included, as were any drugs reported ≥ 100 times. We performed a descriptive comparison of reports for the same drugs used in non-COVID-19 indications. The data lock point date was 7 June 2020. Results In total, 2573 reports were identified for drugs used in the treatment of COVID-19. In order of frequency, the most reported ADRs were electrocardiogram QT-prolonged, diarrhoea, nausea, hepatitis, and vomiting in males and diarrhoea, electrocardiogram QT-prolonged, nausea, vomiting, and upper abdominal pain in females. Other hepatic and kidney-related events were included in the top ten ADRs in males, whereas no hepatic or renal terms were reported for females. COVID-19-related reporting patterns differed from non-pandemic reporting for these drugs. Conclusion Review of a global database of suspected ADR reports revealed sex differences in the reporting patterns for drugs used in the treatment of COVID-19. Patterns of ADR sex differences need further elucidation..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
---|---|
Enthalten in: |
Drug safety - 43(2020), 12 vom: 25. Sept., Seite 1309-1314 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Zekarias, Alem [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Anmerkungen: |
© The Author(s) 2020 |
---|
doi: |
10.1007/s40264-020-01000-8 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2121481168 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | OLC2121481168 | ||
003 | DE-627 | ||
005 | 20230504184404.0 | ||
007 | tu | ||
008 | 230504s2020 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/s40264-020-01000-8 |2 doi | |
035 | |a (DE-627)OLC2121481168 | ||
035 | |a (DE-He213)s40264-020-01000-8-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
084 | |a 15,3 |2 ssgn | ||
084 | |a PHARM |q DE-84 |2 fid | ||
100 | 1 | |a Zekarias, Alem |e verfasserin |0 (orcid)0000-0003-0297-8881 |4 aut | |
245 | 1 | 0 | |a Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © The Author(s) 2020 | ||
520 | |a Introduction In late 2019, a new coronavirus—severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)—was discovered in Wuhan, China, and the World Health Organization later declared coronavirus disease 2019 (COVID-19) a pandemic. Numerous drugs have been repurposed and investigated for therapeutic effectiveness in the disease, including those from “Solidarity,” an international clinical trial (azithromycin, chloroquine, hydroxychloroquine, the fixed combination lopinavir/ritonavir, and remdesivir). Objective Our objective was to evaluate adverse drug reaction (ADR) reporting for drugs when used in the treatment of COVID-19 compared with use for other indications, specifically focussing on sex differences. Method We extracted reports on COVID-19-specific treatments from the global ADR database, VigiBase, using an algorithm developed to identify reports that listed COVID-19 as the indication. The Solidarity trial drugs were included, as were any drugs reported ≥ 100 times. We performed a descriptive comparison of reports for the same drugs used in non-COVID-19 indications. The data lock point date was 7 June 2020. Results In total, 2573 reports were identified for drugs used in the treatment of COVID-19. In order of frequency, the most reported ADRs were electrocardiogram QT-prolonged, diarrhoea, nausea, hepatitis, and vomiting in males and diarrhoea, electrocardiogram QT-prolonged, nausea, vomiting, and upper abdominal pain in females. Other hepatic and kidney-related events were included in the top ten ADRs in males, whereas no hepatic or renal terms were reported for females. COVID-19-related reporting patterns differed from non-pandemic reporting for these drugs. Conclusion Review of a global database of suspected ADR reports revealed sex differences in the reporting patterns for drugs used in the treatment of COVID-19. Patterns of ADR sex differences need further elucidation. | ||
700 | 1 | |a Watson, Sarah |0 (orcid)0000-0001-9660-5968 |4 aut | |
700 | 1 | |a Vidlin, Sara Hedfors |0 (orcid)0000-0003-1619-3751 |4 aut | |
700 | 1 | |a Grundmark, Birgitta |0 (orcid)0000-0002-2799-9374 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Drug safety |d Springer International Publishing, 1990 |g 43(2020), 12 vom: 25. Sept., Seite 1309-1314 |w (DE-627)130833363 |w (DE-600)1018059-X |w (DE-576)43551685X |x 0114-5916 |7 nnns |
773 | 1 | 8 | |g volume:43 |g year:2020 |g number:12 |g day:25 |g month:09 |g pages:1309-1314 |
856 | 4 | 1 | |u https://doi.org/10.1007/s40264-020-01000-8 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a FID-PHARM | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OPC-PHA | ||
951 | |a AR | ||
952 | |d 43 |j 2020 |e 12 |b 25 |c 09 |h 1309-1314 |